Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials MYELOMATCH MASTER PROTOCOL

What's the purpose of this trial?

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

This trial is currently open and accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

* Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS.
* Participants must be \>= 18 years of age.
* Participants must not have received prior anti-cancer therapy for AML or MDS.

* Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
* Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction.
* Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure.

* Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment.
* Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy

* Note: active hormonal therapy is allowed
* Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration.
* Participants must agree to have translational medicine specimens submitted.
* Participants must be offered the opportunity to participate in specimen banking.

* Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.

* Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
* The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.

Additional Trial Information

Phase 2

Enrollment: 2,000 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Arizona

Banner Health University Medical Center

Tucson, AZ

Open and Accepting

University of Arizona Cancer Center

Tucson, AZ

Open and Accepting

California

Connecticut

Smilow Cancer Hospital at Yale New Haven

New Haven, CT

Open and Accepting

Idaho

Kootenai Cancer Center

Post Falls, ID

Open and Accepting

Illinois

OSF St. Joseph Medical Center (Bloomington)

Bloomington, IL

Open and Accepting

Illinois CancerCare (Bloomington)

Bloomington, IL

Open and Accepting

Illinois CancerCare (Canton)

Canton, IL

Open and Accepting

Illinois CancerCare (Carthage)

Carthage, IL

Open and Accepting

Carle Foundation Hospital (Vermilion)

Danville, IL

Open and Accepting

Cancer Care Specialists of IL - Cancer Care Center of Decatur

Decatur, IL

Open and Accepting

Memorial Health - Decatur Memorial Hospital Memorial Health

Decatur, IL

Open and Accepting

Northwestern Medicine Cancer Center (Kishwaukee)

DeKalb, IL

Open and Accepting

Illinois CancerCare-Dixon

Dixon, IL

Open and Accepting

Cancer Care Specialists (Crossroads Cancer Center)

Effingham, IL

Open and Accepting

Carle (Effingham)

Effingham, IL

Open and Accepting

Illinois CancerCare (Eureka)

Eureka, IL

Open and Accepting

Illinois CancerCare (Galesburg)

Galesburg, IL

Open and Accepting

Northwestern Medicine Cancer Center Delnor

Geneva, IL

Open and Accepting

NorthShore University Health System Glenbrook Hospital

Glenview, IL

Open and Accepting

Northwestern Medicine Grayslake Outpatient Center

Grayslake, IL

Open and Accepting

Illinois CancerCare (Kewanee)

Kewanee, IL

Open and Accepting

Northwestern Medicine Lake Forest Hospital

Lake Forest, IL

Open and Accepting

Illinois CancerCare (Macomb)

Macomb, IL

Open and Accepting

Carle Foundation Hospital (Mattoon)

Mattoon, IL

Open and Accepting

Northwestern Medicine Orland Park

Orland Park, IL

Open and Accepting

Illinois CancerCare - Fox River Cancer Center

Ottawa, IL

Open and Accepting

Illinois CancerCare - Pekin

Pekin, IL

Open and Accepting

Illinois CancerCare - Peoria

Peoria, IL

Open and Accepting

Methodist Medical Center of Illinois

Peoria, IL

Open and Accepting

OSF Saint Francis Medical Center

Peoria, IL

Open and Accepting

Illinois CancerCare - Peru In Valley Regional Cancer Center

Peru, IL

Open and Accepting

Illinois CancerCare - Princeton

Princeton, IL

Open and Accepting

Southern Illinois University School of Medicine - Simmons Cancer Institute

Springfield, IL

Open and Accepting

Springfield Clinic 1st - 900 Building

Springfield, IL

Open and Accepting

Memorial Medical Center

Springfield, IL

Open and Accepting

Carle Cancer Institute

Urbana, IL

Open and Accepting

Northwestern Medicine Cancer Center Warrenville

Warrenville, IL

Open and Accepting

Illinois CancerCare - Washington

Washington, IL

Open and Accepting

Iowa

Mission Cancer & Blood (Clive) In Clive Cancer Center

Clive, IA

Open and Accepting

MercyOne Des Moines Medical Center

Des Moines, IA

Open and Accepting

Mission Cancer MercyOne Cancer Center (Laurel)

Des Moines, IA

Open and Accepting

Kansas

Hays Medical Center

Hays, KS

Open and Accepting

University of Kansas Cancer Center

Kansas City, KS

Open and Accepting

Olathe Medical Center

Olathe, KS

Open and Accepting

University of Kansas Cancer Center (Overland Park)

Overland Park, KS

Open and Accepting

University of Kansas Cancer Center (Indian Creek)

Overland Park, KS

Open and Accepting

Salina Regional Health Center

Salina, KS

Open and Accepting

University of Kansas Cancer Center (Westwood)

Westwood, KS

Open and Accepting

Michigan

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, MI

Open and Accepting

IHA Hematology Oncology at St. Joe's Brighton

Brighton, MI

Open and Accepting

IHA Hematology Oncology at St. Joe's Chelsea

Chelsea, MI

Open and Accepting

Genesee Hematology Oncology, PC - Michigan Cancer Research Consortium

Flint, MI

Open and Accepting

Genesys Hurley Cancer Institute

Flint, MI

Open and Accepting

Hurley Medical Center

Flint, MI

Open and Accepting

St. Mary Mercy Hospital St. Joe's Health

Livonia, MI

Open and Accepting

Mississippi

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Columbus, MS

Open and Accepting

Baptist Cancer Center-Grenada

Grenada, MS

Open and Accepting

Baptist Memorial Hospital and Cancer Center-Union County

New Albany, MS

Open and Accepting

Baptist Memorial Hospital and Cancer Center-Oxford

Oxford, MS

Open and Accepting

Baptist Memorial Hospital and Cancer Center-Desoto

Southhaven, MS

Open and Accepting

Missouri

Siteman Cancer Center at Barnes-Jewish West County Hospital

Creve Coeur, MO

Open and Accepting

Truman Medical Center

Kansas City, MO

Open and Accepting

Kansas City Cancer Centers (North)

Kansas City, MO

Open and Accepting

Kansas City Cancer Center (Lee's Summit)

Lees Summit, MO

Open and Accepting

Siteman Cancer Center at Christian Hospital

Saint Louis, MO

Open and Accepting

Siteman Cancer Center at Saint Peters Hospital

Saint Peters, MO

Open and Accepting

Siteman Cancer Center (South St. Louis County)

St. Louis, MO

Open and Accepting

Montana

Providence St. Patrick Hospital

Missoula, MT

Open and Accepting

Nebraska

Nebraska Medicine (Bellevue Medical Center)

Bellevue, NE

Open and Accepting

Nebraska Medicine (Village Pointe)

Omaha, NE

Open and Accepting

Nevada

OptumCare Cancer Care at Seven Hills

Henderson, NV

Open and Accepting

Optum Care Cancer Center - Charleston

Las Vegas, NV

Open and Accepting

OptumCare Cancer Care at Fort Apache

Las Vegas, NV

Open and Accepting

Ohio

Case Western Reserve University

Cleveland, OH

Open and Accepting

Oklahoma

University of Oklahoma Health Sciences Center

Oklahoma City, OK

Open and Accepting

Oregon

Providence Newberg Medical Center

Newberg, OR

Open and Accepting

Providence Willamette Falls Medical Center

Oregon City, OR

Open and Accepting

Oregon Health and Science University OHSU Knight Cancer Institute

Portland, OR

Open and Accepting

Pennsylvania

Abramson Cancer Center - University of Pennsylvania (UPENN) University of Pennsylvania

Philadelphia, PA

Temporarily Suspended

Thomas Jefferson University Hospital

Philadelphia, PA

Open and Accepting

Tower Health Reading Hospital

West Reading, PA

Open and Accepting

South Carolina

Prisma Health Cancer Institute - Spartanburg

Boiling Springs, SC

Open and Accepting

Prisma Health Cancer Institute - Easley Easley

Easley, SC

Open and Accepting

Greenville Health System Cancer Institute (Butternut)

Greenville, SC

Open and Accepting

Prisma Health Cancer Institute - Faris

Greenville, SC

Open and Accepting

Prisma Health Cancer Institute - Eastside Eastside

Greenville, SC

Open and Accepting

Prisma Health Cancer Institute - Greer Greer

Greer, SC

Open and Accepting

Prisma Health Cancer Institute - Seneca Lila Doyle Drive

Seneca, SC

Open and Accepting

Tennessee

Baptist Memorial Hospital and Cancer Center-Collierville

Collierville, TN

Open and Accepting

Baptist Clinical Research Institute

Memphis, TN

Open and Accepting

Virginia

UVA Cancer Center University of Virginia Health System

Charlottesville, VA

Open and Accepting

Massey Cancer Center Virginia Commonwealth University (VCU Health)

Richmond, VA

Open and Accepting

Wisconsin

D. N. Greenwald Center

Mukwonago, WI

Open and Accepting

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, WI

Open and Accepting

ProHealth Waukesha Memorial Hospital

Waukesha, WI

Open and Accepting

UW Cancer Center at ProHealth Care

Waukesha, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message